Authors
Latest:
Select Ongoing Clinical Trials of PARP Inhibitors in Breast CancerMark E. Robson, MD, discusses the progress that has been seen in breast cancer care with the use of PARP inhibitors.
Latest:
Discontinuing Statins in Patients with Life-Limiting IllnessesAmy P. Abernethy, MD, PhD, associate professor, School of Nursing, director, Duke Center for Learning Health Care, Duke University School of Medicine, discusses the results of a multisite randomized trial that examined continuing versus discontinuing statins in the setting of life-limiting illness.
Latest:
The Rationale for Dostarlimab Monotherapy In MSI-H and MSS Endometrial CancerAna Oaknin, MD, head of the Gynecologic Tumors Unit, Vall d’Hebron University Hospital, and principal investigator, Gynecological Malignancies Group, explains the rationale for analyzing anti–PD-1 monotherapy with dostarlimab in patients with microsatellite instability–high and microsatellite stable endometrial cancer.
Latest:
Dramatic Response to Olaparib in a Patient With Metastatic Castration- Resistant Prostate CancerMolecular tumor profiling is rapidly driving personalized medicine within oncology. The value of identifying a targetable mutation using next-generation sequencing for available therapies or clinical trials cannot be underestimated. Herein, we review essential considerations in the initial assessment, specialty referral, and sequencing of treatment for advanced prostate cancer with an identified actionable mutation.
Latest:
Results for the Combination of Nivolumab and Ibrutinib in Non-Hodgkin Lymphoma and CLLAnas Younes, MD, chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center, discusses results from a trial studying the combination of nivolumab and ibrutinib for the treatment of patients with relapsed non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Latest:
Collaboration Between Oncologists and Pathologists Benefit PatientsAndre Goy, MD, MS, discusses the benefits of working with a pathologist to develop a better understanding of molecular oncology and optimal treatment decisions for patients with lymphomas.
Latest:
An Update on Avelumab as Monotherapy for Urothelial CarcinomaAndrea Apolo, MD, medical oncologist at the National Cancer Institute and chief of the bladder cancer section of the Genitourinary Malignancies Branch, discusses the recent updates presented at the 2017 ESMO Annual Congress regarding avelumab (Bavencio) monotherapy for patients with urothelial carcinoma.
Latest:
Exploring Cabozantinib With Nivolumab and Ipilimumab in Urothelial CarcinomaAndrea B. Apolo, MD, principal investigator and the head of the Bladder Cancer Section in the Genitourinary Malignancies Branch at the National Cancer Institute’s Center for Cancer Research, discusses a phase I study of cabozantinib (Cabometyx) plus nivolumab (Opdivo) and cabozantinib plus nivolumab with ipilimumab (Yervoy) in patients with refractory metastatic urothelial carcinoma and other genitourinary tumors.
Latest:
Treatment With a Monocyte-Targeting Agent for Pancreatic CancerAndrea Wang-Gillam, MD, PhD, discusses a trial looking at PF-04136309, an investigational chemokine receptor antagonist, in combination with FOLFIRINOX for the treatment of locally advanced pancreatic cancer.
Latest:
Extending Progression-Free Survival in Ovarian Cancer With PazopanibAndreas du Bois, MD, a professor of gynecologic oncology at Kliniken Essen Mitte in Essen, Germany, discusses a phase III trial exploring the effectiveness of treatment with maintenance pazopanib for patients with advanced ovarian cancer.
Latest:
Enhancing Benefit With Durvalumab in NSCLC After the PACIFIC TrialAndreas Rimner, MD, gives an overview of his presentation titled, “Crossing the PACIFIC,” which he presented at the 2019 New York Lung Cancers Symposium. He evaluates some potential next steps for durvalumab (Imfinzi) following the practice-changing results from the PACIFIC trial.
Latest:
Dr. Andrew Branagan on A New Flu Vaccine for Patients With MyelomaBranagan said in his study, which gave patients with myeloma a high-dose flu vaccine followed by a booster dose 30 days later, 66% of patients saw total serum protection from the ailment. he said previous efforts to vaccinate patients with myeloma has resulted in a 20% total serum protection.
Latest:
Subcutaneous Regimen Shows Non-Inferiority for HER2+ Breast CancerAndrew Seidman, MD, discusses the FeDeriCa trial of intravenous versus subcutaneous trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer.
Latest:
Pushing Ahead With New Treatments for Nonmetastatic Castration-Resistant Prostate CancerPatients with the localized form of CRPC still have no options that are proven to extend overall survival, but preliminary results from the PROSPER trial of enzalutamide and the SPARTAN trial of apalutamide offer them unprecedented hope.
Latest:
PEGPH20 With Nab-paclitaxel/Gemcitabine in Pancreatic CancerAndrew Hendifar, MD, MPH, assistant professor of medicine, Cedars Sinai Medical Center and the David Geffen School of Medicine, discusses PEGPH20 with nab-paclitaxel/gemcitabine in pancreatic cancer.
Latest:
Identifying the Link Between Breast Cancer and ObesityAndrew J. Brenner, MD, PhD, assistant professor of medicine, clinical investigator, Cancer Therapy Research Center, The University of Texas Health Science Center, discusses a study that was conducted to try to find the link between obesity and breast cancer.
Latest:
Expert Shares Rationale for GSI Plus CAR T-Cell Combination in MyelomaAndrew J. Cowan, MD, explains the rationale for a phase I clinical trial in which a gamma-secretase inhibitor was combined with CAR T-cell therapy as treatment for heavily pretreated patients with multiple myeloma.
Latest:
Combinations, Sequencing Will Optimize HR+ Breast Cancer Treatment, Expert SaysWilliam J. Gradishar, MD, summarizes the need for new strategies to alter the landscape of HR-positive breast cancer for the better, and how these methods can overcome drug resistance and delay disease progression.
Latest:
An Explanation of SIR-SpheresAndrew Kennedy, MD, physician-in-chief, Radiation Oncology, Sarah Cannon, director, Radiation Oncology Research, Sarah Cannon Research Institute, explains what SIR-Spheres are and how they are used.
Latest:
Unmet Needs and Emerging PV TherapiesDr. Kuykendall provides his perspective on the biggest unmet needs with current advanced PV therapies, emerging data he is following that may impact future management, and any other clinical pearls for optimal PV management.
Latest:
Exploring the Combination Anti-CTLA-4 and Anti-PD-1 in Multiple Myeloma Post-TransplantAndrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the significance of his findings when combining an anti-CTLA-4 and anti-PD-1 in patients with multiple myeloma. He sought out to find whether these 2 drugs could be combined safely after an autologous stem cell transplant.
Latest:
Pecora Highlights Major Areas of Investigation in Multiple MyelomaAndrew L. Pecora, MD, FACP, CPE, discusses the biggest areas of research in the field of multiple myeloma. Pecora says that there has been a surprising number of advances in the field, with current research mostly focused on 1 of 3 areas.
Latest:
Expert Explains Why He Uses BV Plus AVD Instead of BEACOPP in Hodgkin LymphomaDuring a Targeted Oncology Case-Based Roundtable, Andrew M. Evens, DO, MSc, discussed testing and treatment for a 22-year-old patient with Hodgkin lymphoma.
Latest:
Brentuximab Vedotin Adds Benefit to A+AVD Therapy in cHLAndrew M. Evens, DO, MSc, discusses the significance of the results from the phase III ECHELON-1 trial in which patients with stage III/IV classical Hodgkin lymphoma were treated with the combination of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine.
Latest:
Selecting Patients for Treatment with CO-1686Andrew R. Allen, BM, BCh, MA, MRCP, PhD, Executive Vice President of Clinical and Pre-Clinical Development, Chief Medical Officer, Co-Founder, Clovis Oncology, discusses how patients are selected for treatment with CO-1686.
